Literature DB >> 1543597

Ruptured aneurysms of the sinus of Valsalva.

L Lukács1, I Bartek, A Haán, J Hankóczy, A Arvay.   

Abstract

From 1969 to 1989, 15 patients with an aneurysm of the sinus of Valsalva underwent operative correction. This represents 0.23% of 6515 cardiac operations with cardiopulmonary bypass during that time. There were 8 males and 7 females ranging in age from 15 to 54 years (mean 35.8 years). Symptoms of congestive heart failure, fatigue and palpitation were common. All patients underwent cardiac catheterization including aortography. Associated lesions included aortic valve regurgitation in 6 patients and a ventricular septal defect in 3 patients. The following connections occurred: right coronary sinus to right ventricle (8 patients), right coronary sinus to both right atrium and right ventricle (1 patient), and noncoronary sinus to right atrium (6 patients). The aneurysm was repaired via aortotomy or through the chamber into which it emptied. The aortic valve was replaced in 2 patients. There were no early or late postoperative deaths. Fourteen patients were in NYHA functional class I at late follow-up (range 0.5 to 20.5 years, mean 8.7 years). There have been no recurrences. Our experience supports the concept that early surgical intervention in patients with ruptured aneurysms of the sinus of Valsalva is justified.

Entities:  

Mesh:

Year:  1992        PMID: 1543597     DOI: 10.1016/1010-7940(92)90092-c

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  2 in total

1.  Repair of a ruptured sinus of Valsalva aneurysm. Associated with annuloaortic ectasia and coarctation of the aorta in a patient with Marfan syndrome.

Authors:  U F Tesler; R Fiorilli; P Lisanti
Journal:  Tex Heart Inst J       Date:  1997

2.  Surgical correction of ruptured aneurysms of the sinus of Valsalva using on-pump beating-heart technique.

Authors:  Ansheng Mo; Hui Lin
Journal:  J Cardiothorac Surg       Date:  2010-05-14       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.